# Clinical Trials in Kazakhstan

Y 2022 Research report

## Location Data

Kazakhstan is the second largest country between all of the former Soviet Union republics with its population of 19,5 million people[1]. The country has a large and very diverse population, with a sufficient number of trained workers in Healthcare industry.

- Ethnically diverse treatment-naïve patient population.
- Most of the population is concentrated in a few major cities, where healthcare centers are usually well-equipped medical facilities.
- Motivated patient population in search of better care.
- Moderate investigator fees.
- Low number of studies per patient

Russia, together with Kazakhstan, Belarus, Armenia and Kyrgyzstan as members of Eurasian Economic Union concluded the agreement of unified principles and rules for circulation of drugs and medical devices entered into force on 12 Feb 2016, which facilitated clinical trials conduct in these countries and made it transparent to partners.

There is an opportunity for pharmaceutical companies and CROs of unified electronic drug registration within the Union: when it is possible to run clinical trials in one of the member states and then apply for marketing authorization in any of the remaining participating countries through a simplified procedure.

For clients that are looking to initiate new studies and prefer to avoid potential study conduct challenges in the Russian Federation, Kazakhstan offers a cost-effective alternative location. SRG was the first CRO to establish itself in Kazakhstan and has 15 years' experience in delivering high quality clinical trials.

## Trial Data

During the Year 2022 there were 9 clinical trials initiated in Kazakhstan including local and bioequivalence studies. That represents a 18% decline rate in comparison with the previous year when 11 studies were initiated. The majority of clinical trials conducted in Kazakhstan in the Year 2022 were observational studies with a 78% market share.

The only clinical trial with the clearly defined Phase (III) initiated in Kazakhstan during the Year 2022 was related to Oncology. In accordance with the past 5 years' data another prominent therapy areas included Infectious diseases, Mental Health, Cardiology, Diseases of Musculoskeletal System, and Gastroenterology.

**Clinical Trials in Kazakhstan (Y 2015 - Y 2022)**




## Sponsor Data

By country of origin, the U.S. was the key player in Year 2022 in interventional clinical trials (Bayer). As for observation studies, the domestic Sponsors – Astana Medical University and Asfendiyarov Kazakh National Medical University – were the key (and the only) players.

## Subject Data

The overall number of subjects enrolled (or planned to be enrolled) in clinical trials initiated in Kazakhstan in the Year 2022 was just 405 participants of the only Phase III study. In contrary, there were 4,500 subjects enrolled (or planned to be enrolled) into observational studies during the same year.

## About The Orange Paper

The Orange Paper is a free publication produced by Synergy Research Group for the pharmaceutical industry since 2007. It pulls together data from numerous public sources into a single brief document to aid decision makers planning to conduct clinical trials.

It is produced quarterly, with an annual summary at the close of each year.

All of the data within this document are actual on date: 28/04/2023

## About Synergy Research Group

Synergy Research Group is a contract research organization successfully operating in Russia and Kazakhstan since 2002.

From year to year our company is consistently in TOP-10 of market leaders by the numbers of conducted clinical studies and enrolled patients.

The high recruitment rates of the emerging markets combined with innovative technology allows Synergy to offer our clients conduct faster, more cost-effective studies without sacrificing quality for our clients

For all of clinical studies conducted by our company we've set up the highest level of world-class quality both for SOPs and for final study data.

We're continuously working on improvements of our SOPs, study risk management and IT infrastructure – and replacing an outdated R&D strategies by novel, more efficient approaches to clinical research.